valu usd unless otherwis note
debat introduc easi stock
maintain sp lower price target
view leav decis spin legaci busi make strateg
sens also take easi stori introduc
valuat debat well-own stock perhap unfair expect
keytruda concentr becom bigger theme competitor data
lower-risk add question lower price target
maintain sector perform see stock range-bound near-
look past larg in-lin guid ep within
buysid expect rang focu stand-alone
valu lower price target new detail pro-forma
model analys exhibit bigger focu
mrk remain-co ep growth fall
valu first growth acceler consolid
revenu ep cagr legaci
remov spin-co increas per
exhibit time keytruda revenu exposur increas
second question much
worth valu legaci spinco ev/ebitda get us per
share exhibit leav remain-co per share impli
ep see framework exhibit
sever linger question remain unclear
sever mani may address today sell-sid lunch reach
us color afterward hold oper margin
ramp bp ep us
sound oper effici larg offset dis-synergi
near term question especi given ou
overlap need infrastructur separ ii
billion proce lever spin-co assum
use share repurchas provid sensit analysi exhibit
iii well-own safeti stock sell-sid buy respond
new question around valuat keytruda concentr
like fewer near-term import catalyst think upsid
case harder make least near-term
read-through like question
dilut skyrizi/rinvoq growth asset beyond dividend
support peer go way ii think posit read
peer asset emerg along potenti consolid target
remain top idea iii set launch women
health consolid market would buy basket
stock agrx within coverag call today link
price prior trade day market close estimate unless otherwis note
invest thesi merck keytruda remain
key growth driver busi next sever
year declin busi segment continu
throw steadi cash strateg early-
stage deal augment pipelin diversifi busi
long-term thesi base follow key point
support sector perform rate
see continu strong growth ahead
keytruda still plenti runway loss
exclus loe concern becom urgent issu
seen stock sell three year ahead meaning
loe cliff give merck plenti time
keytruda loe compani growth larg
driven keytruda sever tailwind
maintain momentum
bolt-on deal help diversifi mix augment
pipelin help compani navig keytruda loe
long runway loe limit urgenc near-term
larger deal allow concentr bolt-on
strategi though uncertainti given pend ceo
transit also see room potenti portfolio prune
declin busi unit
merck margin expans stori compel
rel uniqu among peer continu oper
leverag busi compani shift primari
care toward specialty/oncology/hospit focu redirect
spend effici segment
potenti catalyst data read focu phase readout
keytruda
adjuv tnbc
metastat tnbc pneumococc
vaccin continu busi develop
augment pipelin new ceo announc
close spin women health biosimilar legaci
risk thesi competit risk keytruda
particularli nsclc bmy/azn greater-than-
expect price pressur busi greater
suppli pressur expect gardasil continu
limit growth ahead new manufactur come on-line
bloomberg capit market estim upside/downside/target
base-cas scenario see price target impli
price-to-earnings remainco ep
assum keytruda remain primari growth driver
busi market leader nsclc
continu steadi oper margin expans
compani shift resourc away primari care
modest declin price across portfolio
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
upside-cas scenario see price target impli
price-to-earnings remainco ep
better-than-expect growth margin expans larg
driven keytruda
lack meaning competit challeng keytruda
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
downsid case scenario see price target
impli price-to-earnings remainco ep
greater competit impact keytruda expect
slower uptak key geographi china
wors price pressur anticip across portfolio
disappoint key pipelin data read
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
introduc pro-forma stand-alone model merck remainco newco
stand-alone basi model ep merck remainco reflect
full separ newco busi make two import assumpt directli
influenc ep assum half billion proce newco
redeploy toward share repurchas deliv ep support ii
model million year-on oper effici add anoth ep
without two offset stand-alone remainco ep would
altern merck redeploy proce toward repurchas achiev
million year oper effici remainco ep would increas
howev also risk dis-synergi could underst lead
exhibit remainco stand-alone ep assum newco special dividend redeploy
remainco pro-forma compound-annual-growth-rate improvementrevenu growth increment net oper efficienciesoper margin oper effici per year beg incom pro-forma margin pro-forma target assum total ebitda margin pro-forma assum total less legaci ladd incom lpre-tax incom incom non-controlling lpro forma net pro-forma ep increment share buybacksremainco pro-forma ep newco div use buyback pro-forma ep newco div use buyback share close share share count case assum newco dividend redeploy share buyback share count newco dividend redeploy share buyback tax-fre receiv special tax-fre dividend newco upon closetax capit structurecom net b/sless special dividend receiv special tax-fre dividend newco upon closeadd dividend use case assum newco dividend redeploy share buyback pro-forma net ebitda equiti equiti pt impli ev/ebitda valuat remainco forecastsimpli equiti equiti merck co inc
newco model ep assum million increment
stand-alon cost dis-synergi biggest differ forecast
merck guidanc pertain newco growth outlook specif model low-single-
digit revenu eros base wherea merck guid low-single-digit
revenu growth result also model flat instead grow margin err
side caution pend detail newco growth initi rate
meaning swing factor valuat
exhibit newco stand-alone ep assum million increment stand-alon cost
modifi price target methodolog merck account plan newco
spin still use large-cap pharma price target framework exhibit appli
sole pro-forma remainco busi deriv valu per share
make chang adjust factor influenc target multipl
separ valu newco stub use ev/ebitda multipl roughli compar
yield per share collect two compon gener
newco pro-forma growth increment stand-alon costsoper margin stand-alon assum year newco revenueoper incom margin pro-forma rang year assum total mrkebitda forma newco ebitda low-to-mid rang year assum total mrkless newco cost newco debtpre-tax incom incom forma net pro-forma capit structurecommentsnewco pro-forma net newco expect initi net ebitda equiti equiti pt impli ev/ebitda valuat newco forecast roughli compar impli equiti equiti exhibit large-cap pharma price target framework new price target merck consist attribut
remainco attribut newco
merck continu trade modest premium large-cap biopharma peer shown
exhibit perspect price target framework impli price-to-earnings base
stand-alone remainco ep think warrant
exhibit large-cap biopharma ntm price-to-earnings despit recent pullback share merck
continu trade modestli peer averag
p/eev/ebitda averagem track recorddividend yieldgrowth profilelo risk p/eev/ebitdashar cap net debtenterpris valueshar estimate net leverageimpliedotherpriceimplieddebt adj target adjust price target repres addit valu attribut plan newco spin captur pro-forma estim note adjust price target repres addit valu relat myl/viatri contribut captur estim forecast total averageadjust factor /- valuat exhibit varianc
variancerbc vs actualstreet vs actualyr yr qtrreportedrbc estimate varianceconsensusvarianceprior yearvari tax net ep dilut analysisgross net incom billionoper expenseshigh low single-digit rateeffect tax billion share exhibit revenu build
merck revenu us patent thru eu spc inject loe sep inject loe feb ped excl possibl allianc revenu astrazenecaunit revenu eisaiunit unit us patent thru eu spc lower stockpil proquad/m-m-r unit exhibit revenu build contd
merck revenu acut us patent pend eu patent loe juli limit gx loe dec loe june loe certain market earli gener competit began loe april acut unit acut acut europ russia eu patent europ russia remain exclusivityimmunolog unit us patent japan patent unit us patent eu japan patent unit exhibit revenu build contd
merck revenu loe dec loe japan loe loe april japan loe lead commerci right eu japan patent unit us/eu patent thru declin due continu price us patent eu patent unit gx launch expect other expect first wh productunit us patent eu patent sold japan women unit exhibit revenu build contd
merck revenu remain exclus major marketunit patent major market expiredunit gener competitionunit loe market us japanfollistim eu japan formul patent expir unit risk-adjust new pipelineunit unit product longer disclosedtot unit unit net exhibit
merck incom guid billioncost product profit guid gross guid sg flat guid increas investmentoper incom guid opex low single-digit rate increaseinterest incom expens incom expens guid expenseearn incom tax tax guid earn earn ep guid share share guid billion sharesdividend per yield base price base price targetebitda estimateebitda guid gross guid profit analysi guid guid sg flat guid increas investmentoper share per merck co inc
price target base equal price-to-earnings ev/ebitda remainco estim use
multipl respect get us per share ad per
share contribut newco spin close multipl use reflect
price target framework appli premium histor industri averag
give compani credit high-growth profil off-set portfolio
concentr impli return price target support sector perform rate
risk rate price target
risk rate price target includ limit tail valu risk loss
exclus loe concern januvia primarili keytruda busi
develop risk compani continu activ posit long-term
growth portfolio diversif outsid keytruda focus smaller/earlier-stag
asset inher riski pipelin risk work develop acquir
intern develop asset pricing/polit risk broadli applic
sector particularli around pricing/reimburs
merck global biopharmaceut compani base kenilworth nj compani report
two segment anim health segment compris
human health pharmaceut product segment sever differ busi unit
largest oncolog vaccin
